Skip to main content
SpringerLink
Log in

Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b

  • Papers Presented at a Symposium on Interferons in Oncology, Budapest, 26th August, 1986
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Interferon alfa-2b (Intron A; Schering-Plough) was administered to 36 patients with chronic myeloid leukemia (CML) at an initial dose of 4 × 106 IU/m2 daily subcutaneously, adapted to changes in leukocyte counts during the course of treatment. Of 32 patients who could be fully evaluated (20 men and 12 women; median age, 34 years) 29 were in the chronic phase, one had a blast crisis and two had accelerated phase disease.

Hematologic remission was achieved in 20 of the 32 patients, while a partial hematologic remission was obtained in 10. Elevated pretreatment white-cell counts returned to normal in 25 patients after 3–40 weeks. There was a parallel decrease in platelet counts after an average treatment time of six weeks and in lactate dehydrogenase, after 2–20 weeks. In conclusion, administration of interferon alfa-2b resulted in a relatively rapid cell reduction in chronic phase CML. The long-term effect of this treatment on the course of the disease and the place of interferon alfa-2b in the overall concept of CML treatment remains to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Amer J Med 63:125, 1977

    Google Scholar 

  2. Canellos GP: Chronic granulocytic leukemia. Med Clin N Amer 60:1001, 1976

    Google Scholar 

  3. Koeffler HP, Golde DW: Chronic myelogenous leukemia-new concepts. (First part) New Eng J Med 304:1201, 1981

    Google Scholar 

  4. Rowley JD: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.) 243:290, 1973

    Google Scholar 

  5. Sokal JE, Gomez GA: The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia. J Clin Oncol 4:104, 1986

    Google Scholar 

  6. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, De Klein A, Bartram CR, Grosveld G: Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature (Lond.) 306:239, 1983

    Google Scholar 

  7. De Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Neisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (Lond.) 300:765, 1982

    Google Scholar 

  8. Shtivelman E, Lifshitz B, Gale RP, Canaani E: Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature (Lond.) 315:550, 1985

    Google Scholar 

  9. Koeffler HP, Golde DW: Chronic myelogenous leukemia — new concepts. (Second part) New Eng J Med 304:1269, 1981

    Google Scholar 

  10. Silver RT, Gale RP: Chronic myeloid leukemia. Amer J Med 80:1137, 1986

    Google Scholar 

  11. Gollerkeri MP, Shah GB: Management of chronic myeloid leukemia. A five-year survey with a comparison of oral busulfan and splenic irradiation. Cancer (Philad) 27:596, 1971

    Google Scholar 

  12. Griffin JD: Management of chronic myelogenous leukemia. Semin Hematol 23: 20, 1986

    Google Scholar 

  13. Hester JP, Waddell CC, Coltman CA Jr, Morrison FS, Stephens RL, Balcerzak SP, Baker LH, Chen TT: Response of chronic myelogenous leukemia patients to COAP-splenectomy. Cancer (Philad) 54:1977, 1984

    Google Scholar 

  14. Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ: Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia. J Clin Oncol 3:192, 1985

    Google Scholar 

  15. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AWG, Batchelor R, Hale G, Waldmann H, Reid CD, Hows J, Gordon-Smith E, Catovsky D, Galton DAG: Bone marrow transplantation for patients with chronic myeloid leukemia. New Eng J Med 314:202, 1986

    Google Scholar 

  16. Mahmoud HK, Schaefer UW, Schüning F, Beelen D, Becher R, Schmidt CG, Alberts W, Haralambie E, Linzenmeier G, Stollmann B, Grosse-Wilde H, Richter HJ, Hantschke D, Luboldt W: Bone marrow transplantation for chronic granulocytic leukemia. Klin Wschr 63:560, 1985

    Google Scholar 

  17. Thomas ED, Clift RA, Fefer A, Applebaum FR, Besinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, Flournoy N, Greenberg P, Hansen JA, Martin P, McGuffin R, Ramberg R. Sandes JE, Singer J, Stewart P, Storb R, Sullivan K, Weiden PL, Witherspoon R: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155, 1986

    Google Scholar 

  18. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocytemacrophage (CFU-GM) progenitor cells. J Immunol131:1300, 1983

    Google Scholar 

  19. Talpaz M, Spitzer G, Hittelman W, Beran M, Gutterman JU: Leukocyte interferon treatment effect on granulocyte/monocyte-colony forming cells in chronic myelogenous leukemia Philadelphia positive patients. Proc Amer Ass Cancer Res 23:273, 1985

    Google Scholar 

  20. Tomida M, Yamamoto Y, Hozumi M: Stimulation by interferon of induction of differentiation of human promyelocytic leukemia cells. Biochem Biophys Res Commun 104:30, 1982

    Google Scholar 

  21. Williams OCK, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JF: Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38:356, 1981

    Google Scholar 

  22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer (Philad) 47:207, 1981

    Google Scholar 

  23. Metz U, Kurschel E, Niederle N, Oehl S: Urinary enzymes in the detection of the nephrotoxic potential of recombinant human α-interferon. In Bach PH, Lock EA (Eds): Renal Heterogeneity and Target Cell Toxicity (John Wiley & Sons: Chichester-New York-Brisbane-Toronto-Singapore) 267, 1985

    Google Scholar 

  24. Talpaz M, McCredie KB, Mavligit GM, Gutterman JU: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62:689, 1983

    Google Scholar 

  25. Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG: α2-Interferon: erste behandlungsergebnisse bei der chronischen myeloischen Leukämie. Dtsch med Wschr 111:767, 1986

    Google Scholar 

  26. Maxwell BL, Talpaz M, Gutterman JU: Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN) therapy. Int J Cancer 36:23, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (Cancer Research), University of Essen, West Germany

    Norbert Niederle, Otto Kloke, Dieter May, Reinhard Becher, Rainhardt Osieka & Carl Gottfried Schmidt

Authors
  1. Norbert Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Kloke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dieter May
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reinhard Becher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rainhardt Osieka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carl Gottfried Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niederle, N., Kloke, O., May, D. et al. Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b. Invest New Drugs 5 (Suppl 4), S19–S25 (1987). https://doi.org/10.1007/BF00207259

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00207259

Key words

Search

Navigation